European Society of Cardiology Congress

Kazem Rahimi, MD, discusses his recent IPD analysis highlighting the consistent relative risk reduction of first cardiovascular event with BP-lowering drugs.

Selvanayagam shares his thoughts on whether ICDs’ improvements in sudden cardiac death are worth the reduced quality of life.

Joseph Selvanayagam, MBBS, discusses the potential of implantable cardioverter-defibrillators to reduce sudden cardiac death among younger patients.

Astrid Paul Nordin, MD, PhD, discusses the results of the IDEAL-AF trial, highlighting the efficacy of including LVZ on top of PVI.

Anjali Owens, MD, discusses the long-term extension of the EXPLORER-HCM trial, demonstrating mavacamten’s safety and efficacy up to 5 years after initiation.

Sten Rubertsson, MD, PhD, discusses the results of the DISCO study, which compared immediate to deferred angiography in patients without ST-elevation following cardiac arrest.

John Ostrominski, MD, discusses his analysis of the FINEARTS-HF trial, which showed finerenone’s improvements despite CKD, ASCVD, and/or metabolic disease.

Jonathan Piccini, MD, discusses his presentation at ESC 2026 discussing the potential benefits of catheter ablation in concomitant HFpEF and AF.

Luke Laffin, MD, discusses his secondary analysis of the phase 2 KARDINAL trial, which demonstrated substantial improvements in uncontrolled hypertension.

The novel cardiac sarcomere modulator from Edgewise Therapeutics saw substantial improvements in both nonobstructive and obstructive HCM after 12 weeks.

Sadiya Khan, MD, MSc, discusses the session she chaired at ESC 2026, which saw clinicians discuss the equitability of artificial intelligence in medicine.

Oyvind Lie, MD, PhD, MSc, discusses the results from the ACASA-TAVI trial, which sought to evaluate the efficacy of anticoagulant monotherapy in this population.

Ankeet Bhatt, MD, MBA, discusses the effectiveness of text, email, and secure portal message reminders for encouraging patients to keep up with their treatment.

Catch up on data from some of the most impactful trials presented at the European Society of Cardiology Congress 2026.

Sharmila Dorbala, MD, MPH, discusses how this treatment and imaging strategy may lead to a diagnostic overhaul for patients with amyloidosis.

Rahul Aggarwal, MD, MBA, shares the results of his retrospective cohort study investigating the residual risk of heart failure after patients with prior MI.

Pooled data from 3 trials show H-ISDN cuts all-cause and cardiovascular death in HFrEF, though heterogeneity limits clinical impact.

Deepak Bhatt, MD, MPH, MBA, discusses the next steps for pacibekitug in cardiovascular disease following its success in the phase 2 trial.

A post hoc ALPACA analysis presented at ESC Congress 2026 shows lepodisiran cut Lp(a)-bound oxidized phospholipids by up to 94% at the 400-mg dose.

Deepak Bhatt, MD, MPH, MBA, discusses the efficacy of this investigational IL-6 antibody among patients at high inflammatory risk.

Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, break down CARDIO-TTRansform and the new 2026 ESC heart failure guidelines.

The ASPIRED trial found immediate ECG monitoring in the ED did not reduce recurrent syncope but doubled arrhythmia detection and cut mortality.

The investigational therapy did not achieve statistical significance in KCCQ-TSS or in 6MWD, but saw substantial changes in exploratory secondary endpoints.

H-ISDN missed its primary endpoint in H-HeFT, but a pooled meta-analysis found significant reductions in all-cause and cardiovascular death in HFrEF.

Christie Ballantyne, MD, unpacks SHASTA-3/4 results on plozasiran for severe hypertriglyceridemia, from triglyceride reduction to pancreatitis prevention.

SHASTA-3 and SHASTA-4 found plozasiran cut triglycerides by roughly 80% and acute pancreatitis events by 78% in severe hypertriglyceridemia.

Ashish Sarraju, MD, discusses phase 1 data showing a single dose of Kylo-11 durably reduced lipoprotein(a) through 48 weeks.

Luke Laffin, MD, discusses 1-year data showing CTX310 produced durable reductions in ANGPTL3, LDL cholesterol, and triglycerides.

Ronald Witteles, MD, explains why CARDIO-TTRansform's miss doesn't undermine TTR silencers as a class for treating ATTR-CM.

Phase 2b LUMINARA results showed the oral relaxin agonist AZD5462 improved echocardiographic measures of cardiac function in patients with chronic heart failure.